Zenas BioPharma Enters a ~$300M Funding Agreement with Royalty Pharma to Support Obexelimab Development

Shots:Zenas BioPharma has entered into an agreement with Royalty Pharma granting it royalty rights on the future sales of obexelimabAs per the deal, Zenas will receive ~$300M, consisting of a $75M upfront & 3 additional $75M each in milestones tied to P-III (INDIGO) trial achievement & FDA approvals in IgG4-RD & SLE, while Royalty Pharma…

ByRidhi RastogiSeptember 4, 2025

NEWS

Royalty Pharma Signs Agreement to Acquire Interest in Amgen’s Imdelltra Royalties from BeOne Medicines for ~$950M

Shots:Royalty Pharma has acquired a royalty interest in Amgen’s Imdelltra from BeOne Medicines for ~$950MAs per the deal, Royalty Pharma will acquire BeOne’s ~7% royalty on global Imdelltra sales for ~$950M, including $885M upfront and an option for BeOne to sell more for $65M within 12mos. The royalty, including shared sales above $1.5B…

ByDipanshu DixitAugust 26, 2025

NEWS

Royalty Pharma Purchases Revolution Medicines’ Royalty Rights of Daraxonrasib for ~2B

Shots:Royalty Pharma acquiring Revolution Medicines’ royalties for daraxonrasib (P-III RASolute 302), providing up to $1.25B across five $250M milestone tranches, plus an additional $750M debt facility in three tranchesRevolution received the $250M upfront, with future payments tied to P-III data (2026), FDA approval (by Jan 2028), and sales milestones, allowing access to further…

ByPrince GiriJune 25, 2025

NEWS

Royalty Pharma Partners with Biogen to Develop Litifilimab

Shots:Royalty Pharma & Biogen have entered into an agreement for the clinical development of litifilimab in SLE & CLE As per the agreement, Biogen will receive ~$250M R&D funding over 6 quarters to support the development, whereas Royalty Pharma is entitled to receive regulatory milestones & mid-single digit royalties on global sales …

ByRidhi RastogiFebruary 13, 2025

INSIGHTS+

PharmaShots’ Key Highlights of Third Quarter 2022

The third quarter of 2022 highlights the approvals, clinical data & acquisitions. There are major alliances in this quarter which include CVS Health acquired Signify Health for ~$8B, Amgen acquired Chemocentryx for ~$4BThe third quarter of the year also showcases multiple approvals of the therapies which include Incyte's Opzelura US FDA's approval for Vitiligo,…

BySenior EditorSeptember 29, 2022

Zenas BioPharma Enters a ~$300M Funding Agreement with Royalty Pharma to Support Obexelimab Development

Royalty Pharma Signs Agreement to Acquire Interest in Amgen’s Imdelltra Royalties from BeOne Medicines for ~$950M

Royalty Pharma Purchases Revolution Medicines’ Royalty Rights of Daraxonrasib for ~2B

Royalty Pharma Partners with Biogen to Develop Litifilimab

PharmaShots’ Key Highlights of Third Quarter 2022

Contact US

OUR INFORMATION

FOLLOW US